Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2024-09-19 Regulatory Filings
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges regarding the dissolution of a wholly owned foreign subsidiary, Dr. Lal PathLabs Kenya Private Limited. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to material events or disclosures by listed entities. The content includes details about the subsidiary's financial parameters and the fact of its dissolution, but it does not contain financial statements, earnings data, or detailed management discussion. The document is a regulatory announcement about a corporate event (subsidiary dissolution) rather than a financial report or management report. It is not a full annual or interim report, nor an earnings release or capital update. Given the nature of the disclosure and the regulatory reference, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice (1400 characters) informing the stock exchanges about the schedule of an upcoming analyst/institutional investor meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The document does not contain any financial data, results, or detailed presentations. It is an announcement of a meeting schedule rather than the meeting materials or transcript itself. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS) rather than an Investor Presentation (IP) or Call Transcript (CT).
2024-09-16 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to stock exchanges in India. It concerns a notice to equity shareholders about unclaimed equity shares related to an interim dividend from FY 2017-18, which are due for transfer to the Investor Education and Protection Fund (IEPF) as per the Companies Act, 2013. The document includes a newspaper advertisement and mentions that individual notices have been sent to shareholders. There is no financial data, earnings information, or detailed report content. The document is an official regulatory announcement related to compliance and shareholder notification, not a financial report or management discussion. It is also not a voting result, board change, or capital change announcement. Given the nature of the disclosure and the regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-12 English
Updates
Capital/Financing Update Classification · 95% confidence The document is an official disclosure to stock exchanges regarding the sanctioning of a Scheme of Amalgamation by the National Company Law Tribunal (NCLT) involving two subsidiary companies of Dr. Lal PathLabs Limited. It references compliance with SEBI Listing Regulations and provides detailed information about the merger, including rationale, share exchange ratio, and business details. The document is a regulatory announcement about a corporate restructuring event (amalgamation) rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but serves as an update on a significant corporate transaction. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as mergers and amalgamations.
2024-09-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated September 4, 2024, addressed to stock exchanges, informing about the schedule of upcoming analyst and institutional investor meetings. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The content is purely an announcement of scheduled meetings with investors and analysts, with no financial data, report, or detailed presentation included. The document length is only 1513 characters, indicating it is a brief announcement rather than a full report or presentation. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to investor meetings, but since it does not contain the actual presentation or detailed financials, it is more accurately classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about upcoming investor meetings without substantive financial content or report attached.
2024-09-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q1 FY25 earnings conference call for Dr. Lal PathLabs. It includes management presentations, financial performance highlights, and a Q&A session with investors and analysts. The text explicitly mentions it is a transcript of the earnings call, with detailed financial data such as revenue, EBITDA, PAT, EPS, and operational highlights. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls including earnings calls with Q&A. The document is about 15,000 characters long, contains substantive financial data and management discussion, and is not merely an announcement or a summary. Therefore, the correct classification is CT with high confidence.
2024-08-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.